A UCLA clinical trial found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing deep, durable responses including complete tumor regression.
UCLA researchers developed lipid nanoparticle-based gene editing that inserts a complete CFTR gene into human airway cells, restoring up to 100% of normal channel function in cystic fibrosis laboratory models without viral vectors.
A UCLA study found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing complete tumor regression despite no overall survival advantage.
